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Abstract
Objectives: To describe a group of patients treated at our service for Henoch-Schönlein purpura, with emphasis
on recurrent and chronic cases, and to compare clinical and demographic characteristics of patients with monocyclic
and recurrent disease.
Methods: Data on 67 patients who had been treated since disease onset were analyzed. Twelve patients were
excluded because they failed to return for follow-up consultations after less than 3 months, leaving a total of 55
children in the study sample. Recurrence was defined as the presence of a fresh episode after a period of at least 3
months without symptoms, and cases were defined as chronic when cutaneous, abdominal and renal manifestations
persisted for a period of 12 months or more.
Results: Recurrence was observed in 8/55 patients (14.4%) and four cases were chronic (7.2%). In 29/55
patients (52.7%), infection was identified as the trigger factor. A monocyclic clinical course was observed in 43
patients (26 of whomwere girls, with amean age of 5.4 years). Gastrointestinal and renal involvement was observed
in 55.8 and 20.9% of patients, respectively. Among the 12 patients with recurrent or chronic Henoch-Schönlein
purpura, three had arthritis, four exhibited signs and symptoms of abdominal involvement and seven of kidney
disease: microscopic hematuria in five, macroscopic hematuria in one and hematuria with proteinuria in one other.
Late onset was the only variable related to recurrence (p < 0.05).
Conclusions:As is observed inmedical literature,monocyclic cases aremore commonamong childrenwith early
onset disease. Patients with Henoch-Schönlein purpura should be followed over the long term, since recurrent and
chronic cases account for more than 20% of the total.
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Introduction
Henoch-Schönlein purpura (HSP) is the most common
type of systemic vasculitis in childhood and is characterized
by palpable, non-thrombocytopenic purpura, sometimes
accompanied by arthritis and/or arthralgia, abdominal pains,
hemorrhage gastrointestinal and/or nephritis.
Although its cause is unknown, it is known that
immunoglobulin A (IgA) plays an important role in its
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immunopathogenesis. In up to 50% of cases, an upper
respiratory infection (URI) precedes the disease by days or
weeks.1,2 It has been suggested that group A beta-hemolytic
streptococcus may be a trigger factor, as may the use of
medicines and vaccines and contact with specific food
allergens, such as colorings and preservatives.1,2
Approximately one third of patients have at least one
recurrence, generally involving cutaneous and abdominal
manifestations, especially during a 2-year period after the
first outbreak.1-3
Some patientsmay progresswith chronic kidney disease,
characterized by glomerulonephritis, systemic arterial
hypertension and compromised renal function.4,5
The objective of this study was to describe a group of
patients treated for HSP at our service, putting emphasis on
describing recurrent and chronic cases.
Methods
This study received prior approval from theMedical Ethics
Committeeat theUniversidadeFederal deSãoPaulo/Hospital
São Paulo.
Medical records were reviewed retrospectively for
patients whowere first seen at our service between 1995 and
2004, presenting with HSP. Diagnosis was made based on
American College of Rheumatology criteria.6 A minimum
follow-up period of three months was one of the inclusion
criteria. Cases were excluded if they had merely been
referred for a specialist opinion, as were patients who ceased
attending follow-up appointments for whatever reason, and
those with comorbidities.
The demographic (age and sex), clinical (trigger factor,
presence of purpura, arthritis, abdominal pains, gastrointes-
tinal hemorrhage and renal involvement) and therapeutic
characteristics (corticoids and prophylaxis with benzathine
penicillin) of 55 patients were studied. At our service, we are
currently prescribing benzathine penicillin every 21 days, for
a period varying from six to 24 months, for patients with
recurrent or chronic HSP, even in the absence of serological
evidence of streptococcal infection, based on the possibility
that the true the disease is triggered by Streptococcus, which
is a common bacterium in our country. Also routine, is oral or
intravenous corticoid in cases of moderate/severe
gastrointestinal involvement, pulmonary hemorrhage,
central nervous system involvement and orchiepididimitis.
When there is renal involvement, depending on the
histological results of the kidney biopsy, it may become
necessary to use immunosuppression, with azathioprine
being the drug of choice at our service in the majority of
cases.
Recurrencewasdefinedas thepresenceof a freshepisode
after a period of at least 3monthswithout signs or symptoms.
Cases were defined as chronic when cutaneous,
gastrointestinal and/or renal manifestations persisted for a
continuous period of 12 months or more.
The following definitions were adopted for renal
involvement: microscopic hematuria (> 10 erythrocytes/
field), macroscopic hematuria (> 100 erythrocytes/field),
proteinuria (> 5 mg/kg/24 h) and systemic arterial
hypertension (> 90th percentile for arterial systolic and
diastolic pressure for age and stature).
Trigger factors were investigated by means of interviews
with parents, and included the occurrence of infections
(upper/lower airway infections or acute gastroenterocolitis),
consumption of foods to which the patient is not accustomed
and use of medicines or vaccinations during the 7 days prior
to onset of clinical status.
Statistical analysis was performed using Student’s t test
for continuous variables andwither Fisher’s or the chi-square
test for categorical variables. Results were considered
statistically significant where p < 0.05.
Results
Demographic and clinical data on the 55 patients are
presented in Table 1. Recurrence was observed in eight
patients (14.4%) and four (7.2%) cases were chronic.
When we compared the subset of patients with
monocyclic disease (n = 43 patients) with the subset of
patients with recurrent or chronic cases (n = 12), we
observed that there was a significant difference between
their mean ages (5.4 vs. 8.4 years, respectively; p = 0.011).
Twenty-seven patients were given corticoids, and in 21 of
these the indication was gastrointestinal involvement. There
were no cases of severe complications, such as intestinal
bleeding or perforation. Where it was necessary to give
corticoid therapy intravenously, we usedmethylprednisolone
at dosagesof 1 to2mg/kg/day, split between two to four daily
doses, always in association with intravenous ranitidine. The
corticoid of choice for oral route was prednisolone or
prednisone, also in association with oral ranitidine. Six
patients were also given corticoids because of orchitis or
severe cutaneous involvement.
All eight patients who relapsed exhibited cutaneous
manifestation in their later attacks. Additionally, three
patientspresentedarthritis; fourabdominal pains; andseven
had renal involvement: microscopic hematuria (n = 5),
macroscopic hematuria (n = 1) and hematuria with
proteinuria (n = 1).
Four patients progressed chronically (altered urinary
sedimentation) and underwent renal biopsy. One 9-year-old
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girl with chronic cutaneous and renal involvement exhibited
necrotizing mesangial proliferative diffuse glomerulitis with
increasing fibrocells andmesangial IgA and C3 deposits. One
6-year-old boy with macroscopic hematuria was diagnosed
with diffuse proliferative mesangial glomerulonephritis with
IgAdeposits. An11-year-old girl who continues to suffer from
hematuria and proteinuria exhibitedmesangial IgA deposits.
Finally, minimal lesions were observed in a 10-year-old girl
with hematuria and proteinuria lasting 18 months.
Patients with recurrent purpura exhibited a greater
frequency of renal involvementwhen comparedwith patients
with monocyclic disease (p = 0.015). We also observed that
arthritis present during the first attack correlated with
chronic cases (p = 0.022).
Discussion
Monocyclic HSP is most often vasculitis observed in
day-to-day pediatric practice. Nevertheless, around 20 to
30% of patients may exhibit relapse, especially during the 2
years following their first episode.2,3 In this study we
observed recurrence and chronicity rates of 14.4 and 7.2%,
respectively.
There are descriptions of HSP affecting children of all
ages, being more prevalent in schoolchildren.2,7 In Brazil,
Silva et al. have observed peak incidence at 6 years of age,
which is similar to the findings with our patient sample.
Observed frequency was greater among girls (31 girls vs. 24
boys), in contrast with the literature, where a majority of
studies report a discrete male predominance.1,3,7-9
Sano et al.10 assessed 134 HSP patients and observed
that age of more than 4 years at disease onset was
associated, among other factors,with renal involvementwith
worse prognosis. We did not observe any association
between age and renal prognosis; however we did note a
correlation with relapse rate, i.e. the mean age of patients
with recurrent disease was greater than that of patients with
monocyclic cases (8.4 and 5.4 years, respectively;
p = 0.011).
It is to be recommended that possible trigger factors be
investigated when dealing with HSP patients, since theymay
be responsible for recurrent cases. In a recent study,
Gonzáles-Gayet al.1 described thepresenceofURI preceding
41% of HSP cases and observed a positive correlation
between this factor and increased incidence of nephritis,
although therewasnoeffect on final diseaseprognosis. Inour
study, we detected a previous history of infection in
approximately 50% of cases, including URI and acute
gastroenterocolitis, with no correlation with recurrence,
chronicity or prognosis. Although many studies have
identified beta-hemolytic streptococcus as a trigger factor for
HSP,1,3,8 there are no controlled studies that confirm the
benefits of benzathine penicillin for prophylaxis against
relapse. In our sample this conduct was indicated for eight
relapsed patients with, all of whom responded well.
No statistically significant relationship was observed
between the use of corticoids and recurrence, chronicity or
prognosis.
Table 1 - Demographic and clinical characteristics of 55 patients with HSP, broken down intomonocyclic or recurrent/chronic
clinical course
Clinical course
Total (n = 55) Monocyclic (n = 43) Recurrent/chronic†(n = 12)
Age (years)* 6.0±2.5 SD 5.4±2.5 SD 8.4±2.4 SD
Sex (female/male) 31/24 (56/44%) 26/17 (60/40%) 5/7 (41/59%)
History of infection 29 (52.7%) 26 (60.4%) 3 (25%)
Purpura 55 (100%) 43 (100%) 12 (100%)
Arthritis 32 (58.1%) 29 (67.4%) 3 (25%)
Abdominal pains 25 (45.4%) 21 (48.8%) 4 (33.3%)
Renal involvement 9 (16.3%) 2 (4.6%) 7 (58.3%)
Microscopic hematuria 7 (12.7%) 2 (4.6%) 5 (41.6%)
Macroscopic hematuria 1 (1.8%) - 1 (8.3%)
Proteinuria and hematuria 1 (1.8%) - 1 (8.3%)
HSP = Henoch-Schönlein purpura; SD = standard deviation.
* p = 0.01.
† The subset of patients with recurrent/chronic clinical course comprised eight patients with recurrent disease and 4 patients with
chronic cases.
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The main determinant of HSP outcome is renal
involvement, affecting 10 to 50% of patients, generally
during the first 3months of the disease.3,9 Themost common
alterations are microscopic hematuria and mild proteinuria.
Other less common findings are nephrotic syndrome and
arterial hypertension, which may correlate with poor
prognosis and chronic renal failure.2,8,10,11 In our sample,we
observed microscopic hematuria in 12.7% of our patients,
with a greater percentage among recurrent cases (41.6%).
Furthermore, in general we observed a significant correlation
(p = 0.015) between renal involvement and the possibility of
cutaneous relapse. Despite the anatomopathological
findings in four of the patients we took biopsies from, none of
them suffered kidney failure. It should be pointed out that
this subset of patients should be followed-up over the long
term, with periodical urinary sediment analyses and renal
function tests (serum urea and creatinine and creatinine
breakdown).
Silva et al.3 reported arthritis and/or arthralgia in 78% of
cases, which is similar to our data (58.1%). Although we
observed a statistically significant relationship between
arthritis and chronic cases (p = 0.022), we should interpret
this finding with caution, since involvement of joints is
common in HSP and no similar data are reported in the
literature.
We suggest the standardization of investigations into
possible trigger factors for chronic and recurrent cases:
question parents and patients about possible infections
suffered by the patient or day-to-day contacts during the 30
days prior to HSP onset and as the disease progresses, and
also a detailed discussion of habitual and abnormal dietary
items, including consumptionof foodswith largequantities or
colorings and preservatives and of medicines such as
vitamins, anti-inflammatories and antibiotics. Investigation
can involve excluding potential triggers from the diet and
performing tests for specific allergens, such as the
radio-allergo-sorbent-test (RAST).
Our data reiterates the need for periodic follow-up of all
children with HSP, especially in cases with renal involvement,
such as, for example, those with persistent hematuria and
proteinuria or arterial hypertension. Urinary sediments
should be monitored, even in asymptomatic patients.
Referral to a specialist (pediatric rheumatologist or
nephrologist) is recommended in caseswhere presentation is
atypical.
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